Dr. Nagpal received her Ph.D. in Biochemical Engineering and Biotechnology from the Indian Institute of Technology Delhi, India. She joined the Agarwal lab at Boston Children’s Hospital in 2016 where she has been developing small molecule strategies to modulate human telomerase in the rare degenerative disease, dyskeratosis congenita (DC). Her work in the past few years has discovered novel chemicals that have the potential to restore telomere maintenance in stem cells derived from patients with DC. Dr. Nagpal is driven to improve the drug-like properties of these molecules to develop the first systemic treatments for DC, pulmonary fibrosis, and other rare telomere biology diseases.